Therapeutic Strategies for Targeting Cell Signaling in TME
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology offers a full range of solutions and services for investigating therapeutic strategies that for target cell signaling in the tumor microenvironment (TME), helping researchers successfully achieve their research goals.
Tumors are a serious threat to human health and life, and people still do not really have a comprehensive understanding of the pathogenic mechanisms of cancer. Recent studies have shown that cell signaling is closely related to the occurrence, development, recurrence and metastasis of tumors. In tumor cells, genetic mutations or overexpression of growth factors or receptors lead to overactivation of receptors, which activates intracellular kinases and activates downstream signaling pathways to promote tumor growth. It has also been demonstrated that multiple signaling pathways, such as the mitogen-activated protein kinase (MAPK) system, IkB kinase/NF-kB (IKK/NF-kB) pathway, Wnt-β-catenin pathway, TGF-β signaling system, and reactive oxygen species (ROS), form a complex network that precisely regulates tumor cell growth, differentiation, migration, and apoptosis.
In recent years, the successful development of targeted drugs related to the regulation of signal transduction networks of tumor microenvironment (TME) and has shown a promising future for human tumor prevention and treatment, but also revealed the importance of target selection.
However, small molecule targeted drugs related to tumor signal transduction pathways still have various limitations and shortcomings. To develop therapeutic strategies with greater specificity and fewer side effects, Alfa Oncology has established an innovative tumor microenvironment center technology platform and is developing several technologies designed to help global collaborators develop therapeutic strategies targeting the tumor microenvironment (TME) and tumor signaling pathways. We are vigorously developing novel multi-targeted drugs, with clinical emphasis on the integration of molecular targets, and conducting in-depth research on therapeutic strategies targeting multi-pathway and multi-targeted signaling pathways to provide clues and basis for individualized precision therapy.
Alfa Oncology offers key strategies for targeting tumor signaling pathways including but not limited to:
- Therapeutic strategies targeting tumor signaling pathways
- Targeting vascular endothelial growth factor receptor (VEGFR) signaling pathway
- Targeting HER and its downstream signaling pathways
- Targeting EGFR T790 mutations
- Targeting ALK signaling pathway
- Targeting c-kit signaling pathway
- Therapeutic strategies to target tumor microenvironment (TME) signaling pathways
- Targeting the main signaling pathways of tumor angiogenesis
- Targeting T-cell activation signaling pathway
- Targeting TCR signaling pathway
- Targeting PD1
- Targeting CTL4
- Targeting IL-2 signaling pathway
Note: The key strategies we focus on are always up to date, please contact us by email for more up-to-date and relevant information.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.